Concentrations of Tenofovir and Emtricitabine in Breast Milk of HIV-1-Infected Women in Abidjan, Côte d'Ivoire, in the ANRS 12109 TEmAA Study, Step 2

ABSTRACT The aim was to evaluate emtricitabine (FTC) and tenofovir (TFV) neonatal ingestion through breast milk. Median TFV and FTC breast milk doses represented 0.03% and 2%, respectively, of the proposed oral infant doses. Neonatal simulated plasma concentrations were extremely low for TFV but between the half-maximal inhibitory concentration and the adult minimal expected concentration for FTC. The rare children who will acquire HIV despite TDF-FTC therapy will need to be monitored for viral resistance acquisition.

[1]  J. Stringer,et al.  Effectiveness of Non-nucleoside Reverse-Transcriptase Inhibitor-Based Antiretroviral Therapy in Women Previously Exposed to a Single Intrapartum Dose of Nevirapine: A Multi-country, Prospective Cohort Study , 2010, PLoS medicine.

[2]  B. Clotet,et al.  Pilot Pharmacokinetic Study of Human Immunodeficiency Virus-Infected Patients Receiving Tenofovir Disoproxil Fumarate (TDF): Investigation of Systemic and Intracellular Interactions between TDF and Abacavir, Lamivudine, or Lopinavir-Ritonavir , 2009, Antimicrobial Agents and Chemotherapy.

[3]  F. Dabis,et al.  Population Pharmacokinetics of Tenofovir in HIV‐1‐Infected Pregnant Women and Their Neonates (ANRS 12109) , 2009, Clinical pharmacology and therapeutics.

[4]  M. Fowler,et al.  Antiretroviral Concentrations in Breast-Feeding Infants of Mothers Receiving Highly Active Antiretroviral Therapy , 2008, Antimicrobial Agents and Chemotherapy.

[5]  B. Chi,et al.  Single-dose tenofovir and emtricitabine for reduction of viral resistance to non-nucleoside reverse transcriptase inhibitor drugs in women given intrapartum nevirapine for perinatal HIV prevention: an open-label randomised trial , 2007, The Lancet.

[6]  B. Masquelier,et al.  Prevalence of resistance to nevirapine in mothers and children after single-dose exposure to prevent vertical transmission of HIV-1: a meta-analysis. , 2007, International journal of epidemiology.

[7]  S. Lagakos,et al.  Response to antiretroviral therapy after a single, peripartum dose of nevirapine. , 2007, The New England journal of medicine.

[8]  B. Kearney,et al.  Pharmacokinetics of Tenofovir in Breast Milk of Lactating Rhesus Macaques , 2005, Antimicrobial Agents and Chemotherapy.

[9]  F. Rousseau,et al.  Pharmacokinetic and pharmacodynamic characteristics of emtricitabine support its once daily dosing for the treatment of HIV infection. , 2004, AIDS research and human retroviruses.

[10]  F. Dabis,et al.  Population Pharmacokinetics of Emtricitabine in HIV-1 infected Pregnant Women and their neonates ( ANRS 12109 ) , 2008 .